4.09
-0.02(-0.49%)
Currency In USD
| Previous Close | 4.11 |
| Open | 4.1 |
| Day High | 4.14 |
| Day Low | 4.05 |
| 52-Week High | 12.36 |
| 52-Week Low | 3.79 |
| Volume | 14.89M |
| Average Volume | 41.33M |
| Market Cap | 1.64B |
| PE | -2.22 |
| EPS | -1.84 |
| Moving Average 50 Days | 4.71 |
| Moving Average 200 Days | 5.1 |
| Change | -0.02 |
If you invested $1000 in Recursion Pharmaceuticals, Inc. (RXRX) since IPO date, it would be worth $130.67 as of January 01, 2026 at a share price of $4.09. Whereas If you bought $1000 worth of Recursion Pharmaceuticals, Inc. (RXRX) shares 3 years ago, it would be worth $541.72 as of January 01, 2026 at a share price of $4.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
GlobeNewswire Inc.
Dec 08, 2025 12:30 PM GMT
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks off therapy (week 25 of the study), 82% of evalua
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
GlobeNewswire Inc.
Dec 01, 2025 1:30 PM GMT
Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Pha
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
GlobeNewswire Inc.
Nov 05, 2025 11:28 AM GMT
Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and PresidentSalt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio c